C
Charles Pyke
Researcher at Novo Nordisk
Publications - 75
Citations - 7756
Charles Pyke is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Stromal cell & Cancer. The author has an hindex of 37, co-authored 69 publications receiving 6946 citations. Previous affiliations of Charles Pyke include University of California, San Francisco & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Anna Secher,Jacob Jelsing,Arian F. Baquero,Jacob Hecksher-Sørensen,Michael A. Cowley,Louise S. Dalbøge,Gitte Hansen,Kevin L. Grove,Charles Pyke,Kirsten Raun,Lauge Schäffer,Mads Tang-Christensen,Saurabh Verma,Brent M. Witgen,Niels Vrang,Lotte Bjerre Knudsen +15 more
TL;DR: These findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Journal ArticleDOI
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke,R. Scott Heller,Rikke Kaae Kirk,Cathrine Ørskov,Steffen Reedtz-Runge,Peter Kaastrup,Anders Hvelplund,Linda Bardram,Dan Calatayud,Lotte Bjerre Knudsen +9 more
TL;DR: Results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLp-1R.
Journal ArticleDOI
Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways.
Leif R. Lund,John Romer,Nicole Thomasset,Helene Solberg,Charles Pyke,Mina J. Bissell,Keld Danø,Zena Werb +7 more
TL;DR: The data support the hypothesis that there are at least two distinct phases of involution: an initial phase, characterized by induction of the apoptosis-associated genes SGP-2 and ICE and apoptosis of fully differentiated mammary epithelial cells without visible degradation of the extracellular matrix, and a second phase, characterize by extrace cellular matrix remodeling and altered mesenchymal-epithelial interactions, followed by apoptotic cells that are losing differentiated functions.
Journal Article
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Charles Pyke,Peter Kristensen,E. Ralfkiaer,J. Grøndahl-Hansen,Jens Eriksen,Francesco Blasi,Keld Dano +6 more
TL;DR: Results support the view that components of the plasminogen activation system may act to influence proteolytic events occurring at the interface between stroma and malignant cells in adenocarcinomas of the colon in humans.
Journal Article
Laminin-5 Is a Marker of Invading Cancer Cells in Some Human Carcinomas and Is Coexpressed with the Receptor for Urokinase Plasminogen Activator in Budding Cancer Cells in Colon Adenocarcinomas
TL;DR: The colocalization of laminin-5 and urokinase-type plasminogen activator receptor in a subset of cancer cells in colon cancer suggests that a controlled up-regulation of a number of gene products is a characteristic of budding colon cancer cells, and that these gene products serve functions crucial for the invasive phenotype of these cancer cells.